Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adar Yaacov

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
International Journal of Molecular Sciences|February 27, 2026
Consensus Copy-Number Alteration Signatures from Clinical Panels Enable Pan-Cancer Risk Stratification and Therapy Response AssociationAdar Yaacov
Patterns (New York, N.Y.)|July 15, 2026
From matching to facilitation: Reframing AI's role in clinical trial enrollmentAdar Yaacov, Einat Levi, Nir Peled
Scientific Reports|May 15, 2023
Mutational signatures association with replication timing in normal cells reveals similarities and differences with matched cancer tissuesAdar Yaacov, Shai Rosenberg, Itamar Simon
Scientific Reports|August 12, 2023
Both cell autonomous and non-autonomous processes modulate the association between replication timing and mutation rateOriya Vardi-Yaacov, Adar Yaacov, Shai Rosenberg, et al.
Medrxiv : the Preprint Server for Health Sciences|June 4, 2026
CBFB mutations predict endocrine therapy benefit in estrogen receptor-positive breast cancerAdar Yaacov, Gal Passi, Roni Gillis, et al.
Cancer Research|October 20, 2022
Shared Cancer Dataset Analysis Identifies and Predicts the Quantitative Effects of Pan-Cancer Somatic Driver VariantsJakob Landau, Linoy Tsaban, Adar Yaacov, et al.
Cell Reports. Medicine|June 12, 2024
Cancer mutational signatures identification in clinical assays using neural embedding-based representationsAdar Yaacov, Gil Ben Cohen, Jakob Landau, et al.
Journal of Clinical Medicine|June 26, 2026
Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center StudyEinav Koren, Adar Yaacov, Jamal Zidan, et al.
Cells|January 9, 2026
The Temozolomide Mutational Signature: Mechanisms, Clinical Implications, and Therapeutic Opportunities in Primary Brain Tumor ManagementAdar Yaacov, Roni Gillis, Jaber Salim, et al.
Cancer Research|October 27, 2021
Cancer Mutational Processes Vary in Their Association with Replication Timing and Chromatin AccessibilityAdar Yaacov, Oriya Vardi, Britny Blumenfeld, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
International Journal of Molecular Sciences|February 27, 2026
Consensus Copy-Number Alteration Signatures from Clinical Panels Enable Pan-Cancer Risk Stratification and Therapy Response AssociationAdar Yaacov
Patterns (New York, N.Y.)|July 15, 2026
From matching to facilitation: Reframing AI's role in clinical trial enrollmentAdar Yaacov, Einat Levi, Nir Peled
Scientific Reports|May 15, 2023
Mutational signatures association with replication timing in normal cells reveals similarities and differences with matched cancer tissuesAdar Yaacov, Shai Rosenberg, Itamar Simon
Scientific Reports|August 12, 2023
Both cell autonomous and non-autonomous processes modulate the association between replication timing and mutation rateOriya Vardi-Yaacov, Adar Yaacov, Shai Rosenberg, et al.
Medrxiv : the Preprint Server for Health Sciences|June 4, 2026
CBFB mutations predict endocrine therapy benefit in estrogen receptor-positive breast cancerAdar Yaacov, Gal Passi, Roni Gillis, et al.
Cancer Research|October 20, 2022
Shared Cancer Dataset Analysis Identifies and Predicts the Quantitative Effects of Pan-Cancer Somatic Driver VariantsJakob Landau, Linoy Tsaban, Adar Yaacov, et al.
Cell Reports. Medicine|June 12, 2024
Cancer mutational signatures identification in clinical assays using neural embedding-based representationsAdar Yaacov, Gil Ben Cohen, Jakob Landau, et al.
Journal of Clinical Medicine|June 26, 2026
Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center StudyEinav Koren, Adar Yaacov, Jamal Zidan, et al.
Cells|January 9, 2026
The Temozolomide Mutational Signature: Mechanisms, Clinical Implications, and Therapeutic Opportunities in Primary Brain Tumor ManagementAdar Yaacov, Roni Gillis, Jaber Salim, et al.
Cancer Research|October 27, 2021
Cancer Mutational Processes Vary in Their Association with Replication Timing and Chromatin AccessibilityAdar Yaacov, Oriya Vardi, Britny Blumenfeld, et al.
Pageof 2